CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 4 Planned sale Chief Technology Officer sold 31,278 shares at $8.82 ($275,947)
- 4 Planned sale See Remarks sold 5,000 shares at $8.83 ($44,169)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Returned to the company 10% owner returned 21,165 shares (to the company)
- 8-K Event Regulation FD disclosure · Other events
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Returned to the company 10% owner returned 31,335 shares (to the company)
Page 7 of 22 · 422 filings